Endurant Capital Management LP Esperion Therapeutics, Inc. Transaction History

Endurant Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$19.4 - $28.71 $1.08 Million - $1.59 Million	-55,540 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$25.12 - $36.89 $3.81 Million - $5.6 Million	-151,753 Reduced 73.21%	55,540 $1.56 Million
Q4 2020 Feb 16, 2021	BUY	$24.2 - $35.76 $1.73 Million - $2.55 Million	71,392 Added 52.53%	207,293 $5.39 Million
Q3 2020 Nov 16, 2020	SELL	$31.18 - $52.71 $1.48 Million - $2.5 Million	-47,348 Reduced 25.84%	135,901 $5.05 Million
Q2 2020 Aug 14, 2020	BUY	$30.04 - $51.31 $5.5 Million - $9.4 Million	183,249 New	183,249 $9.4 Million

207

128M

1.67M

930K

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $155M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Endurant Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Endurant Capital Management LP with notifications on news.